Category overview

MedTech

Diagnostic imaging incumbents and high-end scientific instruments.

ISRGIntuitive Surgical

New 8-K filed 2026-07-27 — not yet processedPrice 39% above estimated priceRevenue remains heavily concentrated in the da Vinci robotic-surgery platform, and a credible competitive threat now targets that concentration: J&J received FDA authorization for its Ottava robot. Near-term impact is limited by ISRG's installed base, $3.4B backlog, and da Vinci 5 ramp (1,464 systems), but competitive share pressure warrants monitoring.

2252.HKShanghai MicroPort MedBot Group

Surgical robotics — laparoscopic, orthopaedic, endoscopic (Toumai)

CNY→HKD 1.1560 as of 2026-07-23

Price 80% above estimated priceEBIT covers interest only -10.6× — operating profit does not cover the interest bill.Trailing-margin DCF likely understates value — the company is scaling into first profitability (trailing EBITDA is negative), so a forecast anchored to last year's margin is conservative. Review with Level-3 assumptions.

2675.HKShenzhen Edge Medical

Surgical robotics — laparoscopic and endoscopic systems

CNY→HKD 1.1560 as of 2026-07-23

Price 75% above estimated priceEBIT covers interest only -162.8× — operating profit does not cover the interest bill.Trailing-margin DCF likely understates value — the company is scaling into first profitability (trailing EBITDA is negative), so a forecast anchored to last year's margin is conservative. Review with Level-3 assumptions.

300760.SZShenzhen Mindray Bio-Medical Electronics

Patient monitoring, in-vitro diagnostics, and medical imaging

Price 33% above estimated price

688271.SHShanghai United Imaging Healthcare

High-end medical imaging systems (CT, MRI, PET/CT, molecular imaging)

688277.SHBeijing Tinavi Medical Technology

Orthopaedic surgical navigation & robotics (TiRobot / 天玑)

Price 85% above estimated priceEBIT covers interest only -13.6× — operating profit does not cover the interest bill.Terminal value is 159% of enterprise value — most of this DCF rests on far-future assumptions. Weight the peer cross-check accordingly.

TWSTTwist Bioscience Corporation

Synthetic DNA manufacturing, NGS tools, and biopharma antibody discovery